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Multiple sclerosis is a chronic inﬂammatory disease of the central nervous system, associated with demyelination and neuro-
degeneration. The mechanisms of tissue injury are currently poorly understood, but recent data suggest that mitochondrial injury
may play an important role in this process. Since mitochondrial injury can be triggered by reactive oxygen and nitric oxide
species, we analysed by immunocytochemistry the presence and cellular location of oxidized lipids and oxidized DNA in lesions
and in normal-appearing white matter of 30 patients with multiple sclerosis and 24 control patients without neurological disease
or brain lesions. As reported before in biochemical studies, oxidized lipids and DNA were highly enriched in active multiple
sclerosis plaques, predominantly in areas that are deﬁned as initial or ‘prephagocytic’ lesions. Oxidized DNA was mainly seen in
oligodendrocyte nuclei, which in part showed signs of apoptosis. In addition, a small number of reactive astrocytes revealed
nuclear expression of 8-hydroxy-D-guanosine. Similarly, lipid peroxidation-derived structures (malondialdehyde and oxidized
phospholipid epitopes) were seen in the cytoplasm of oligodendrocytes and some astrocytes. In addition, oxidized phospholipids
were massively accumulated in a fraction of axonal spheroids with disturbed fast axonal transport as well as in neurons within
grey matter lesions. Neurons stained for oxidized phospholipids frequently revealed signs of degeneration with fragmentation of
their dendritic processes. The extent of lipid and DNA oxidation correlated signiﬁcantly with inﬂammation, determined by the
number of CD3 positive T cells and human leucocyte antigen-D expressing macrophages and microglia in the lesions. Our data
suggest profound oxidative injury of oligodendrocytes and neurons to be associated with active demyelination and axonal or
neuronal injury in multiple sclerosis.
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Multiple sclerosis is a chronic inﬂammatory disease of the CNS,
leading to focal plaques of primary demyelination with a variable
degree of axonal and neuronal degeneration (Lassmann et al.,
2007). Although different mechanisms may contribute to demye-
lination and neurodegeneration in multiple sclerosis, it recently
became clear that mitochondrial injury and subsequent energy
failure is a major factor driving tissue injury (Lu et al., 2000;
Dutta et al., 2006; Mahad et al., 2008; Trapp and Stys 2009;
Witte et al., 2010). Active multiple sclerosis lesions show profound
alterations of proteins of the mitochondrial respiratory chain
(Mahad et al., 2008, 2009) and mitochondrial DNA deletions
are present in neurons, in particular in the progressive stage of
the disease (Campell et al., 2011). Such mitochondrial changes
may explain characteristic pathological features of multiple scler-
osis lesions, including demyelination and oligodendrocyte apop-
tosis (Veto et al., 2010), preferential destruction of small-calibre
axons (Mahad et al., 2008, 2009), differentiation arrest of oligo-
dendrocyte progenitor cells and remyelination failure (Ziabreva
et al., 2010) and astrocyte dysfunction (Sharma et al., 2010;
Campbell et al., unpublished data). Mitochondrial proteins and
DNA are highly vulnerable to oxidative damage (Higgins et al.,
2010), and it is thus expected that free radical-mediated mechan-
isms may drive mitochondrial injury in multiple sclerosis (Lu et al.,
2000; Kalman and Leist, 2003; Mao and Reddy, 2010; van
Horssen et al., 2011). Oxidized lipids and oxidized DNA have
been detected biochemically in brain tissue from patients with
multiple sclerosis (Vladimirova et al., 1998; Smith et al., 1999;
Bizzozero et al., 2005; Quin et al., 2007) and some studies
have analysed their cellular localization in multiple sclerosis lesions
by immunocytochemistry (Newcombe and Cuzner, 1994; Lu et al.,
2000; Van Horssen et al., 2008). The results of the latter studies,
however, are disappointing, since immunoreactivity was seen in
macrophages and astrocytes, but not in those cells or components
that actually are destroyed in the lesions, such as oligodendro-
cytes, neurons and axons. The aim of this study was a systematic
analysis of the presence and location of oxidized DNA and lipids at
a cellular level in different stages of lesion formation in multiple
sclerosis. We show that oxidized DNA and lipids are concentrated
within active portions of the lesions. We further found that oxi-
dized lipids—both oxidized phospholipids and malondialdehyde
(MDA)—are excellent markers for acute cell injury and degener-
ation of neurons and glia. Furthermore, different oxidized lipids
preferentially accumulate in different cell types or cellular
compartments.
Materials and methods
This study was performed on parafﬁn-embedded archival autopsy ma-
terial from 30 patients with multiple sclerosis, one patient with neu-
romyelitis optica and 24 controls without neurological disease or brain
lesions (Table 1). Controls included 17 normal controls of different age
and seven patients, who died under septic conditions. The presence of
concomitant vascular (ischaemic) lesions, which could by itself lead to
oxidative damage in human brain tissue, was excluded by detailed
neuropathological studies, performed on multiple tissue blocks from
each patient. The clinical course was deﬁned by retrospective chart
review according to established criteria before and blinded to the
pathological analysis (Lublin and Reingold, 1996). The multiple scler-
osis cohort included seven cases of acute multiple sclerosis (Marburg,
1906), who died within 1 year after disease onset (Table 1). Further,
two cases of relapsing/remitting multiple sclerosis, 12 cases of second-
ary progressive multiple sclerosis and eight cases of primary progres-
sive multiple sclerosis were included. Due to insufﬁcient clinical data
one additional multiple sclerosis case could only be classiﬁed as pro-
gressive multiple sclerosis. The study was approved by the Ethik
Kommission of the Medical University of Vienna (EK Nr 535/2004).
Neuropathological techniques and
immunocytochemistry
All cases underwent detailed neuropathological examination on mul-
tiple tissue blocks from various brain regions and lesion activity was
evaluated as described in detail previously (Frischer et al., 2009).
Immunocytochemistry was performed on parafﬁn sections according
to established techniques (King et al., 1997; Bauer et al., 2007). A
detailed list of primary antibodies, dilutions and corresponding
pretreatment of sections is shown in Table 2. Since immunocytochem-
ical analysis of oxidized molecules in tissue sections may potentially
lead to false-positive results in sections stained with a peroxidase de-
tection system, an additional detection system, based on alkaline phos-
phatase was used, which showed identical results.
Double labelling was performed using primary antibodies from dif-
ferent species. Oxidative markers were ﬁrst stained using primary anti-
bodies from mouse or goat, followed by respective species-speciﬁc
secondary antibodies, labelled with alkaline phosphatase and develop-
ment in fast blue BB reagent (blue reaction product). Then cell-speciﬁc
rabbit or rat antibodies were applied (TPPP-p25 for oligodendrocytes,
glial ﬁbrillary acidic protein for astrocytes, synaptophysin for axons
with disturbed axonal transport, Iba-1 for macrophages and microglia
and CD3 for T cells). This was followed by species-speciﬁc biotinylated
anti-rabbit or anti-rat immunoglobulin, avidin–peroxidase and devel-
opment in amino ethyl carbazole reagent (red reaction product; for
details see Marik et al., 2007).
Confocal laser ﬂuorescence microscopy
For identifying E06 (oxidized phospholipid)-labelled axonal spheroids,
ﬂuorescence immunohistochemistry was performed on parafﬁn sec-
tions as described above with few modiﬁcations. The primary antibo-
dies, monoclonal anti-E06 and polyclonal anti-synaptophysin, were
applied simultaneously at 4C in a humid chamber overnight. After
washing with phosphate-buffered saline, secondary antibodies consist-
ing of goat-anti-rabbit Cy3 (Jackson ImmunoResearch, 1:200) and
biotinylated anti-mouse (Jackson; 1:500) were applied simultaneously
for 1h at room temperature. The staining was ﬁnished by incubation
with streptavidin-Cy2 (Jackson ImmunoResearch; 1:75) for 1h at
room temperature. Fluorescent preparations were examined using a
Leica SP2 confocal laser scan microscope.
Quantitative analysis
For quantiﬁcation of immunocytochemistry for oxidative markers, two
different approaches were applied. In the ﬁrst approach, we performed
densitometry of sections stained with the antibody against oxidized
phospholipids. In a second approach, we manually counted different
Oxidative damage in multiple sclerosis Brain 2011: 134; 1914–1924 | 1915Table 1 Clinical data of controls and patients with multiple sclerosis included in this study
Clinical multiple
sclerosis type
Age Gender Disease course Total disease
duration (months)
Lesion types
AMS 1 45 Male Monophasic 0.2 Active (Pattern III); inactive
AMS 2 45 Male Monophasic 0.6 Active (Pattern III), inactive
AMS 3 52 Male Monophasic 1.5 Active (Pattern II), inactive
AMS 4 35 Male Monophasic 2 Active (Pattern II; inactive
AMS 5 78 Male Monophasic 2 Active (Pattern III); inactive
AMS 6 34 Female Monophasic 4 Active (Pattern III); inactive
AMS 7 51 Female Monophasic 5 Active (Pattern II), inactive
RRMS 1 40 Female RRMS 120 Active (Pattern III); inactive
RRMS 2 57 Female RRMS 156 Active (Pattern II); inactive
SPMS 1 66 Female SPMS with attacks 96 Inactive
SPMS 2 34 Male SPMS with attacks 4120 Inactive
SPMS 3 62 Female SPMS without attacks 144 Active (Pattern I)
SPMS 4 84 Female SPMS without attacks 264 Inactive
SPMS 5 61 Female SPMS with attacks 288 Slowly expanding active; inactive
SPMS 6 64 Female SPMS without attacks 336 Inactive
SPMS 7 56 Male SPMS without attacks 372 Active (Pattern I); inactive
SPMS 8 76 Male SPMS without attacks 372 Inactive
SPMS 9 78 Female SPMS without attacks 372 Inactive
SPMS 10 69 Female SPMS without attacks 384 Inactive
SPMS 11 81 Female SPMS without attacks 432 Inactive
SPMS 12 46 Female SPMS with attacks 444 Slowly expanding active; inactive
PPMS 1 55 Female PPMS 60 Slowly expanding active; inactive
PPMS 2 67 Male PPMS 87 Active (Pattern I), inactive
PPMS 3 53 Male PPMS 168 Slowly expanding active; inactive
PPMS 4 77 Female PPMS 168 Slowly expanding active; inactive
PPMS 5 34 Female PPMS 204 Slowly expanding active; inactive
PPMS 6 71 Female PPMS 264 Slowly expanding active; inactive
PPMS 7 83 Female PPMS 360 Inactive
PPMS 8 75 Female PPMS 372 Inactive
ProgMS 68 Female Progressive MS 120 Inactive
NMO 20 Female Relapsing NMO 48 Neuromyelitis optica
WMS 1 85 Female Acute stroke 2 days Initial white matter stroke lesion
WMS 2 65 Female Recurrent stroke 48 Initial and advanced stroke lesions
Control 1 30 Female Normal control – –
Control 2 36 Female Normal control – –
Control 3 37 Male Normal control – –
Control 4 39 Female Normal control – –
Control 5 42 Female Normal control – –
Control 6 45 Female Normal control – –
Control 7 46 Male Normal control – –
Control 8 47 Female Normal control – –
Control 9 48 Male Normal control – –
Control 10 65 Male Normal control – –
Control 11 70 Male Normal control – –
Control 12 71 Female Normal control – –
Control 13 71 Female Normal control – –
Control 14 72 Male Normal control -– –
Control 15 83 Male Normal control – –
Control 16 84 Female Normal control – –
Control 17 97 Female Normal control – –
S-Control 42 Female Septic control – –
S-Control 45 Male Septic control – –
S-Control 51 Female Septic control – –
S-Control 74 Male Septic control – –
S-Control 88 Male Septic control – –
S-Control 89 Female Septic control – –
S-Control 95 Female Septic control – –
AMS = acute multiple sclerosis; MS = multiple sclerosis; NMO = neuromyelitis optica; PPMS = primary progressive multiple sclerosis; RRMS = relapsing/remitting multiple
sclerosis; SPMS = secondary progressive multiple sclerosis; WMS = white matter stroke.
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8-hydroxy-D-guanosine (oxidized DNA), E06 (oxidized phospholipids),
MDA2 (malondialdehyde–lysine), CD3 (T cells), Human leucocyte
antigen-DP, DQ, DR (HLA-D; mainly macrophages and microglia)
and amyloid precursor protein (dystrophic axons with disturbed
axonal transport).
Densitometric analysis
By means of Luxol fast blue Kluver’s staining as well as haematoxylin
eosin staining and proteolipid protein immunocytochemistry, regions of
interest (n=761, each 0.61mm  0.46mm) were deﬁned and num-
bered, giving each individual region an ID. The locations of these re-
gions were chosen on the basis of multiple sclerosis pathology differing
between types of multiple sclerosis lesions or normal-appearing white
matter. Photomicrographs were taken from the corresponding regions
in the E06-stained slides under standardized conditions (identical set-
tings, controlled by white balance values) with a Reichert Polyvar 2
microscope using Nikon NIS-Elements D3.10. Pictures were captured
with Gain 1.2 at an exposure time of 6ms. All images were saved as
JPEG ﬁles with lowest compression. They were processed with Adobe

Photoshop CS2, image size was reduced to a width of 10cm and
resolution set on 300 pixel/inch and cold ﬁlter with 25% was applied.
A threshold level (output level = 128) was set and pixels above this
value were deleted. The images were saved as TIF ﬁles and opened
with ImageJ, which measures the per cent area covered by the signal.
The data were structured in order to allow following of each database
value back to the original microscopic image. Averages for individual
densitometric values were calculated per lesion area per case and these
averages were compared between multiple sclerosis samples and white
matter of controls as well as between different lesion areas within the
multiple sclerosis sample.
Manual counting of immunostained
cells or dystrophic axons
Manual counting was performed in the same section areas used for
densitometric analysis. Counting was performed at the microscope in
areas deﬁned by an ocular grid as described previously (Frischer et al.,
2009) for CD3, HLA-D and amyloid precursor protein-stained sections.
For the oxidative markers, counting was performed in 10 microscopic
ﬁelds of 0.25 mm
2 per lesion area. Average counts per square milli-
metre were calculated for each region of interest (normal-appearing
white matter, active lesions, slowly expanding lesions and inactive le-
sions) per case and compared by statistical analysis.
Statistical analysis
Due to the uneven distribution of our data, statistical analysis was
performed with non-parametric tests. Descriptive analysis included
median value and range. Differences between two groups were as-
sessed with Wilcoxon–Mann–Whitney U-test. Differences between
more than two groups were assessed with Kruskal–Wallis test, fol-
lowed by pair-wise Wilcoxon–Mann–Whitney U-tests. In case of mul-
tiple testing (comparison of more than two groups) signiﬁcant values
were corrected with Bonferroni procedure. Interdependence of
Table 2 Antibodies used for immunocytochemistry
Antibody Antibody type Target Source Staining
E06 Mouse (mAB) Oxidized phospholipids Palinski et al., 1996 10mg/ml
E014 Mouse (mAB) Malondialdehyde–lysine Palinski et al., 1996 0.4mg/ml
MDA2 Mouse (mAB) Malondialdehyde–lysine Palinski et al., 1990 1:1000
8-OHdG Goat (polyAB) 8-Hydroxy 2-deoxy Guanosine Abcam, ab10802 1:1000; E
CD3 Rabbit (polyAB) T-cell antigen Dako, A0452 Lot128 1:2000; E
IBA-1 Rabbit (polyAB) Ionized calcium binding adaptor
molecule 1
Courtesy of Dr Sonja Forss-Petter/
Japan
1:3000; E
CD68 Mouse (mAB) CD68 110-kD transmembrane
glycoprotein
Dako, M0814 1:100; E
HLA-D Mouse (mAB) Human leucocyte antigen-DP, DQ,
DR
Dako, M0775 1:100; C
TPPP/p25 Rat (polyAB) Tubulin polymerization promoting
protein
Produced by Gergo ¨ Botond 1:3000; E
CNPase Mouse (mAB) 2’,3’-cyclic nucleotide 3’
phosphodiesterase
Sternberger Monoclonals, SMI91 1:2000; E
MOG Y10 and Z12 Mouse (mABs) Myelin oligodendrocyte
glycoprotein
Piddlesden et al., 1991 1:100; C
PLP Mouse (mAB) Proteolipid protein Serotec, MCA 839G 1:1000; E
APP Mouse (mAB) Alzheimer amyloid precursor
protein
Chemicon, MAB 348 1:1000; C
SY Rabbit (polyAB) Synaptophysin Epitomics YE269, Burlingame, CA,
USA
1:100; E
SMI 32 Mouse (mAB) Non-phosphorylated 200kDa
neuroﬁlament
Sternberger Monoclonals SMI32 1:1000; E
SMI 311 and 312 Mouse (mAB) Neuroﬁlament Sternberger Monoclonals SMI
311 and 312
1:18000; E
GFAP Rabbit (polyAB) Glial ﬁbrillary acidic protein
(intermediate ﬁlament of mature
astrocytes)
Dako, Z0334 Lot 096 1:3000; E
AB = antibody; C = citrate buffer; E =ethylenedinitrilotetraacetic acid buffer.
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The reported P-values are results of two-sided tests. A P-value40.05
was considered statistically signiﬁcant. For all statistical analysis, mean
values per patient for each lesion type and normal-appearing white
matter were used.
Results
Oxidative damage in multiple sclerosis
tissue is related to lesion activity and
inﬂammation
In a ﬁrst approach, we analysed the accumulation of oxidized
DNA and oxidized lipids within multiple sclerosis lesions of differ-
ent activity from patients with acute, relapsing, remitting and pro-
gressive disease by immunocytochemistry. As controls, we used
brain tissue from patients without neurological disease, who died
under conditions of systemic inﬂammation (septic controls) or
non-inﬂammatory conditions (normal controls). Sections were
stained under identical conditions, scanned and evaluated by
densitometry or by manual counting of immunoreactive cells
within the tissue. In comparison with normal and septic controls,
increased immunocytochemical signals were detected in the global
multiple sclerosis population (Figs 1A and B, 2A–C and Table 3).
This was seen in a similar way for markers for oxidized DNA or
lipids. Within multiple sclerosis sections, the highest signal for oxi-
dative damage was found in active lesion areas, while inactive
lesions showed a low signal. Within active lesions, more intense
staining was present in classical active lesions of acute and relap-
sing multiple sclerosis compared with slowly expanding lesions,
which dominate in the progressive stage of the disease. We also
subtyped lesions according to patterns of demyelination
(Lucchinetti et al., 2000). We found higher expression (on average
8.2-fold) of oxidized lipids and oxidized DNA in lesions following
Pattern III (hypoxia-like tissue injury) compared with Pattern II
(complement-associated demyelination). This was seen for global
staining intensity for oxidized phospholipids, determined by densi-
tometry, as well as by counting the number of cells with nuclear
8-hydroxy-D-guanosine reactivity or with cytoplasmic expression
of MDA2. However, due to the low number of cases analysed,
statistical signiﬁcance was reached only for MDA2 (P = 0.01) and
a trend (P = 0.072) for 8-hydroxy-D-guanosine. The values in mul-
tiple sclerosis Pattern II lesions were similar to those seen in a case
of neuromyelitis optica, which was included as a control for
antibody-mediated tissue injury. Interestingly, astrocytes, which
are the primary target for destruction in neuromyelitis optica, did
not show 8-hydroxy-D-guanosine-reactive nuclei. This may be due
to their rapid and efﬁcient antibody- and complement-mediated
destruction. Quantiﬁcation of inﬂammation regarding T cells
(CD3) and macrophages/microglia (HLA-D) revealed a relative dis-
tribution of values, similar to that seen for markers of oxidative
damage. In addition, we found a weak but signiﬁcant correlation
between T cells or macrophages/microglia and the presence of
oxidized DNA or lipids within the sections (data not shown).
Within the global multiple sclerosis population, patients dying in
the course of acute multiple sclerosis showed more accumulation
of oxidized lipids and DNA in the lesions as compared with those
dying in the progressive stage of the disease. The difference, how-
ever, did not reach statistical signiﬁcance. Similarly, we did not see
a signiﬁcant global age- or gender-dependent effect on the pres-
ence of oxidized lipids and DNA in multiple sclerosis or control
cases.
Cellular localization of oxidized DNA
and lipids and its relation to lesion
activity
Fine mapping of actively demyelinating lesions in multiple sclerosis
revealed several different zones, representing the evolution of the
plaques (Figs 1A–F, 2A–G). The centre of an active plaque is
densely packed with foamy macrophages. Towards the edge of
the lesions, macrophage density is even higher, most of them
containing myelin-degradation products, which still have the stain-
ing properties of intact myelin (including even low-abundance
myelin proteins such as myelin oligodendrocyte glycoprotein;
early active lesion according to Bru ¨ck et al., 1995). In between
this area and the normal peri-plaque white matter, there is an-
other zone that contains activated microglia, dispersed between
seemingly intact myelin sheaths, but containing oligodendrocytes
with apoptotic-like nuclear changes. This zone is regarded as the
initial demyelinating lesion (Marik et al., 2007) or the ‘prephago-
cytic’ stage of active multiple sclerosis lesions, as deﬁned by
Barnett and Prineas (2004). Immunoreactivity for oxidized DNA
and oxidized lipids was most prominent in this zone of initial
lesion formation, followed by the adjacent peri-plaque white
matter, but being much lower in the zone of early phagocytic
myelin digestion and nearly absent in the centre of the active
lesion (Figs 1A–F, 2A–G).
Oxidized DNA
Immunocytochemistry for 8-hydroxy-D-guanosine revealed select-
ive staining of cell nuclei, reﬂecting oxidized DNA.
Immunoreactive cell nuclei were most numerous in classical
active lesions (Fig. 1A, B and Table 3), followed by slowly expand-
ing lesions. Low numbers of immunoreactive nuclei were present
in inactive lesions and in the normal-appearing white matter. Only
exceptional nuclei were positive in sections of normal and septic
controls (Fig. 1C). Immunoreactivity for oxidized DNA was mainly
found in areas with profound microglia activation at the lesion
edge (‘initial’ lesion area; Fig. 1A–F). The vast majority of cells
with oxidized DNA were small round cells, morphologically resem-
bling oligodendrocytes (Fig. 1G). Double staining with speciﬁc cel-
lular markers showed oxidized DNA in TPPP-p25-positive
oligodendrocytes, which in part revealed nuclear alterations resem-
bling apoptosis (Fig. 1G). Only 3–4% of cells with 8-hydroxy-D-
guanosine-positive nuclei were astrocytes, identiﬁed by double
staining with glial ﬁbrillary acidic protein (Fig. 1H), and nuclear
reactivity was occasionally seen in neurons in cortical lesions. In
addition, oxidized DNA was seen in some Iba-1- or CD68-positive
1918 | Brain 2011: 134; 1914–1924 L. Haider et al.Figure 1 Oxidized DNA in multiple sclerosis lesions, visualized by immunocytochemistry for 8-hydroxy-D-guanosine (8-OHdG).
(a) Actively demyelinating lesion in a patient with primary progressive multiple sclerosis; the ﬁgure shows areas of the normal-appearing
white matter (NAWM) (left), the zone of ongoing demyelinating activity with profound microglia activation and macrophage inﬁltration
(brown immunoreactivity for the macrophage marker CD68) and the inactive portion of the lesion with low macrophage inﬁltration.
Oxidized DNA (8-OHdG) reactivity is shown as blue nuclei, which are mainly present in the active lesion edge (60). EA = early active
demyelination with macrophages containing myelin-reactive degradation products; initial = initial stage of demyelination with profound
microglia activation and oligodendrocyte apoptosis; LA centre = late active stage of demyelination in lesions centre; macrophages with
neutral lipid degradation products. (b) Higher magniﬁcation of the ‘initial’ stage of the active plaque in a, shows profound microglia
activation (brown cells; CD68 positive) and many blue nuclei, representing cells with DNA oxidation; the asterisks in a and b indicate the
position of b within the lesion shown in a (200). (c) Normal white matter of a control patient without neurological disease and brain
lesions; only very few microglia cells show cytoplasmic CD68 reactivity (brown); there are no blue nuclei, suggesting DNA oxidation
(100). (d) Normal-appearing white matter (NAWM) of a patient with acute multiple sclerosis (Marburg’s type); similar pattern as in the
control white matter, shown in c (100). (e) Very early active lesion area in a patient with acute multiple sclerosis (Marburg’s type);
profound microglia activation (brown cells; CD68) adjacent to cell nuclei, positive for 8-hydroxy-D-guanosine (blue) (100). (f) Late
active lesion centre in a patient with Marburg’s type of acute multiple sclerosis; numerous CD68-positive macrophages (brown), but no
nuclei with blue 8-hydroxy-D-guanosine reactivity (100). (g) Double staining for oxidized DNA (8-hydroxy-D-guanosine; blue) and the
oligodendrocyte marker TPPP-p25 (red) at the lesion edge of an active lesion of acute multiple sclerosis. One of the six oligodendrocytes
shows blue 8-hydroxy-D-guanosine reactivity in a nucleus with nuclear condensation and fragmentation (apoptotic cell) (900). (h)
Double staining for oxidized DNA (8-hydroxy-D-guanosine, blue) and glial ﬁbrillary acidic protein (GFAP, red) at the edge of an active
lesion of acute multiple sclerosis. One astrocyte contains a blue nucleus, indicating oxidized DNA (600). (i) Double staining for oxidized
DNA (8-hydroxy-D-guanosine, blue) and the macrophage marker CD68 (red) in an active lesion of acute multiple sclerosis. The macro-
phage contains a nucleus with oxidized DNA, possibly representing phagocytosis of an apoptotic cell (600). (j) Double staining for
oxidized DNA (8-hydroxy-D-guanosine, blue) and the T-cell marker CD3 (red) in an active lesion of acute multiple sclerosis. No DNA
oxidation is seen in the CD3-positive T-cell population (200).
Oxidative damage in multiple sclerosis Brain 2011: 134; 1914–1924 | 1919Figure 2 Oxidized lipids in multiple sclerosis lesions. (a) Myelin loss in an active white matter lesion in acute multiple sclerosis, Marburg’s
type (8). (b) Adjacent serial section from a, stained with the marker E06 for oxidized phospholipids (OxPL) with profound immunor-
eactivity at the lesion edge and the adjacent peri-plaque white matter (8). (c) Higher magniﬁcation of the sections shown in b, showing
increased immunoreactivity for oxidized phospholipids at the lesion edge (45). (d) Normal white matter of a control patient without
neurological disease or CNS lesions, without immunoreactivity for oxidized phospholipids (45). (e) Peri-plaque white matter (PPWM)
from the area shown in b, with increased immunoreactivity, in comparison with the control white matter, but much lower reactivity as at
the active lesion edge. Immunoreactivity is mostly associated with myelin (150). (f) High immunoreactivity for oxidized phospholipids in
myelin sheaths and some globular structures, representing axonal spheroids, are present at the edge of the active lesions shown in b
(150). (g) Inactive lesion centre of the same lesion shown in b, with low immunoreactivity for oxidized phospholipids; intensive
immunoreactivity, however, is seen in some axonal spheroids (150). (h–k) Oxidized phospholipids are selectively accumulated within
dystrophic axons and axonal spheroids (h, i); the nature of dystrophic axons is documented by double staining confocal microscopy for
oxidized phospholipids and synaptophysin (Syn: j and k)( h, i: 900; j, k: 2500). (l–o) Accumulation of oxidized phospholipids in
neurons in patients with multiple sclerosis with active lesions: (l) lipofuscin reactivity in cortical neuron; (m) ballooned cortical neuron
adjacent to destructive subcortical lesion with intense immunoreactivity for oxidized phospholipids; (n, o) neurons with intense cytoplasmic
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(continued)microglia and macrophages (Fig. 1I) but not in CD3-positive T cells
(Fig. 1J).
Oxidized phospholipids
In both multiple sclerosis and control tissue, E06 immunoreactivity
was seen in lipofuscin granules of macrophages and neurons (Fig.
2L and S). In addition, oxidized phospholipids were present in
multiple sclerosis tissue in various different cell types, predomin-
antly in active white matter and cortical lesions. The most prom-
inent expression was found in acutely injured axons, mainly
located at the edges of actively expanding lesions (Fig. 2H–K).
Reactivity was most intense at the sites of axonal transection
and less in the proximal or distal axon (Fig. 2H and I). Double
staining with synaptophysin revealed a co-localization of oxidized
phospholipids with sites of disturbance of fast axonal transport
(Fig. 2J and K); however, on average only 10% of amyloid pre-
cursor protein-positive axons also contained E06 immunoreactivity
(Table 3). Quantitative analysis showed the highest density of
axonal spheroids containing oxidized phospholipids in active
lesions, followed by slowly expanding lesions, inactive lesions
and normal-appearing white matter (Table 3). Only exceptional
axonal spheroids reactive for oxidized phospholipids were encoun-
tered in brain sections from normal and septic controls (Fig. 2D).
Dense cytoplasmic staining for oxidized phospholipids was also
present in the perinuclear cell bodies and dendrites of some neu-
rons in active lesions in the cortex and the basal ganglia. Many of
the neurons with cytoplasmic staining for oxidized phospholipids
revealed irregularities or fragmentation of their dendritic processes
(Fig. 2M–O).
In addition to neurons and axons, oxidized phospholipids were
also located in myelin (Fig. 2F), in TPPP-p25-positive oligodendro-
cytes (Fig. 2P) and in glial ﬁbrillary acidic protein-positive astro-
cytes (Fig. 2Q and R). While in oligodendrocytes the entire
cytoplasm was stained, in astrocytes the immunoreactivity was
restricted to cytoplasmic inclusions, possibly reﬂecting autophagic
vacuoles. A granular reactivity for oxidized phospholipids was also
seen in the cytoplasm of macrophages, consistent with their con-
tent of lipofuscin (Fig. 2S).
Figure 2 Continued
reactivity for oxidized phospholipids with fragmented cell processes (dendrites) in active lesions in the basal ganglia (h) and cortex
(o)( 600). (p) Active multiple sclerosis lesions; double staining for the oligodendrocyte marker TPPP-p25 (red) and (black/brown),
showing one of the two oligodendrocytes with intense cytoplasmic E06 immunoreactivity (900). (q, r) In astrocytes, oxidized
phospholipids are sequestered in the cytoplasm in the form of larger granules, possibly representing autophagic vacuoles (q: 450;
r: 750). (s) Macrophages with granular cytoplasmic reactivity for oxidized phospholipids in the centre of an active multiple sclerosis
plaque (150). (t) Normal white matter of a control patient without neurological disease or brain lesions; no MDA2 immunoreactivity
(900). (u, v) MDA2 immunoreactivity in oligodendrocytes and myelin in active multiple sclerosis lesions; the nature of the cells as
oligodendrocytes is shown by double staining in v, using TPPP-p25 as a marker (900). (w) Granular cytoplasmic MDA2 immunor-
eactivity (blue) in the cytoplasm of a glial ﬁbrillary acidic protein (GFAP)-positive astrocyte (red) in an active multiple sclerosis lesion
(800). LFB = Luxol fast blue.
Table 3 Quantiﬁcation of oxidized lipids and oxidized DNA in different types of multiple sclerosis lesions in comparison
with controls
Active lesion Slowly expanding lesion Inactive lesion NAWM multiple sclerosis White matter
controls
Median
(range)
P-value* Median
(range)
P-value* Median
(range)
P-value* Median
(range)
P-value* Median (range)
Percentage of E06
positive area
3.1 (26.5) 0.004 1.6 (16.7) 0.245 0.6 (9.2) 0.02 0.8 (17.1) 0.029 0.06 (2.9)
E06 axon spheroids 1.3 (18.2) 0.000 1.2 (121.2) 0.000 0.4 (2.3) 0.000 0.0 (1.2) 0.061 0.00 (0.0)
MDA-2 OG 1.6 (25.8) 0.005 0.9 (5.4) 0.048 0.9 (1.6) 0.286 0.4 (9.2) 0.147 0.00 (1.6)
8-OHdG nuclei 5.6 (78.1) 0.023 9.0 (19.0) 0.136 1.6 (6.8) 0.544 1.4 (12.0) 0.486 0.40 (10.4)
APP 44.3 (197.6) 0.000 16.1 (40.0) 0.000 0.3 (1.5) 0.022 0.0 (1.0) 1.002 0.00 (0.8)
CD3 73.6 (298.8) 0.000 51.2 (105.6) 0.008 10.0 (69.1) 2.835 4.8 (38.4) 0.35 9.60 (49.6)
HLA-D 324.8 (585.6) 0.000 148.3 (398.0) 0.020 29.0 (246.5) 3.718 99.3 (190.0) 0.289 43.10 (114.4)
Values represent medians and range (95th percentile range values); P-values are corrected by Bonferroni for multiple testing; all values represent counted cells/mm
2. Active
lesions = classical actively demyelinating lesions; slowly expanding lesions = lesions with inactive lesion centre, surrounded by a small rim of activated microglia with recent
myelin-degradation products; inactive lesions = lesions without any recent demyelinating activity; NAWM multiple sclerosis = normal-appearing white matter from patients
with multiple sclerosis; white matter controls = normal white matter of all controls; APP = amyloid precursor protein reactive axonal spheroids or end bulbs; CD3 = T cells;
percentage of E06 positive area = densitometric analysis of area covered by E06 immunoreactivity; E06 axon spheroids = axonal spheroids or end bulbs stained by E06
antibody; HLA-D = class II MHC-positive macrophages/microglia; MDA-2 OG = oligodendrocyte-like cells, immunoreactive for MDA-2; 8-OHdG nuclei = number of
cell nuclei containing 8-hydroxy-D-guanosine immunoreactivity; Our data show a highly signiﬁcant accumulation of oxidized DNA and oxidized lipids in active multiple
sclerosis lesions in comparison with controls. Oxidized DNA and lipids are predominantly seen in lesions with high T-cell and macrophage inﬁltrates and with profound
microglia activation. *P-value: Bold values represent signiﬁcant differences (P50.05) in comparison to respective control values.
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Similar to oxidized phospholipids, MDA immunoreactivity was
seen in lipofuscin granules in neurons and macrophages in multiple
sclerosis and control tissue. In multiple sclerosis tissue, additional
staining was predominantly present in myelin sheaths in active
lesions, which in many instances were fragmented. In addition,
reactivity was present in small round cells with morphological fea-
tures of oligodendrocytes (Fig. 2U). These cells could be in part
identiﬁed as oligodendrocytes by double staining with TPPP-p25
(Fig. 2V). Similar to other markers for oxidative damage, the
number and density of MDA-positive oligodendroglial-like cells
was highest in classical active lesions, followed by slowly expand-
ing lesions, inactive lesions and the normal-appearing white matter
(Table 3). MDA2 reactivity was also seen in the cytoplasm of
astrocytes and macrophages. In these cells, reactivity was present
in granular inclusions, similar to the staining pattern for oxidized
phospholipids (Fig. 2W). No MDA2 immunoreactivity was seen in
CD3-positive T cells.
White matter stroke lesions
We have shown before (Aboul Enein et al., 2003) that the pat-
terns of tissue injury in Pattern III multiple sclerosis lesions closely
resemble those seen in the initial stages of white matter stroke
lesions, consistent of microglia activation, distal oligodendroglio-
pathy, oligodendrocyte apoptosis and acute axonal injury, fol-
lowed by demyelination and reactive gliosis. However, in
contrast to multiple sclerosis, these lesions occur in the absence
of major lymphocytic inﬁltrates. Using the same panel of oxidative
markers, as described above, we found very similar distribution of
oxidized DNA and oxidized lipids within the lesions. As in multiple
sclerosis, 8-hydroxy-D-guanosine reactive nuclei were mainly seen
in oligodendrocytes and in neurons within cortical lesions. MDA2
and E06 immunoreactivity was seen in myelin and diffusely in the
oligodendrocyte cytoplasm, while in astrocytes reactivity was se-
questered in lipofuscin-like granules. In addition, numerous axonal
spheroids and end bulbs were reactive for oxidized phospholipids.
Discussion
To date, the mechanisms of tissue injury and neurodegeneration in
multiple sclerosis are poorly understood. Demyelination and axonal
injury occurs on a background of chronic inﬂammation in the
relapsing as well as in the progressive stage of the disease
(Frischer et al., 2009) and close contacts between activated micro-
glia or macrophages and degenerating axons, myelin sheaths and
oligodendrocytes have been described (Ferguson et al., 1997;
Trapp et al., 1998; Kornek et al., 2000). Reactive oxygen species
and nitric oxide intermediates are produced by activated macro-
phages and microglia and are, thus, likely candidates to be
involved in tissue injury in multiple sclerosis (Van Hoorsen et al.,
2010). Indeed, biochemical studies on multiple sclerosis tissue pro-
vided clear evidence for oxidized lipids and DNA within active
multiple sclerosis lesions (Vladimirova et al., 1998; Smith et al.,
1999; Lu et al., 2000) and upregulation of antioxidative proteins
has been reported mainly in astrocytes (Van Hoorssen et al., 2008,
2010). However, attempts to directly localize oxidized molecules
to degenerating oligodendrocytes, axons and neurons have so far
been unsatisfactory. In the current study, immunocytochemistry
for oxidized lipids revealed their presence within macrophages,
located in structures that morphologically resemble lipofuscin.
This is not surprising, since lipofuscin appears to contain
non-digestible remnants of oxidized cellular components, accumu-
lating in macrophages or resident cells of the CNS, for instance
neurons (Keller et al., 2004; Wang et al., 2008). Similarly, nitro-
sylated epitopes, recognized by antibodies against nitrotyrosine,
were mainly seen in macrophages (Cross et al., 1998; Liu et al.,
2001). The only exception is immunoreactivity in oligodendrocytes
for nitrotyrosine, previously described in some active multiple
sclerosis lesions, which suggests a role of peroxynitrite in their
destruction (Jack et al., 2007; Zeis et al., 2009). In contrast to
these previous studies, we show here that DNA and lipid oxidation
is associated with ongoing demyelination and neurodegeneration
in active multiple sclerosis lesions. Furthermore, we show for the
ﬁrst time that acute cell injury and cell death of oligodendrocytes,
axons and neurons in multiple sclerosis is linked to profound cyto-
plasmic and nuclear oxidative damage. The reason for the differ-
ent results between our current and previous studies is not entirely
clear. The most likely explanation comes from our observation that
oxidized DNA and lipids were mainly present in a small zone of
active multiple sclerosis lesions, which represents that previously
described as the area of initial demyelination (Marik et al., 2007)
or the ‘prephagocytic’ lesion (Barnett and Prineas, 2004;
Henderson et al., 2009). Such lesions or lesion areas may not
have been included in earlier studies. It has been shown previously
that oxidized phospholipids and MDA epitopes are present in
apoptotic cells as well as in apoptotic bodies ingested by macro-
phages (Chang et al., 1999). Apoptotic oligodendrocytes are pre-
dominantly seen in multiple sclerosis lesions in areas of initial
(prephagocytic) demyelination (Barnett and Prineas, 2004; Marik
et al., 2007). Furthermore, apoptotic cell death through oxidative
mechanisms may exert pro-inﬂammatory and immunogenic ac-
tions (Chang et al., 2004), which in part may explain the progres-
sive increase in inﬂammation with lesion maturation in multiple
sclerosis (Marik et al., 2007; Henderson et al., 2009).
Analysing DNA oxidation in active multiple sclerosis, we found
that the cells most severely affected are those morphologically
resembling oligodendrocytes and that these cells in part show
condensed and fragmented nuclei, morphologically resembling
apoptosis. These cells could in part be identiﬁed by their expres-
sion of the oligodendrocyte marker TPPP-p25 (Ho ¨ftberger et al.,
2010). Identiﬁcation of dying oligodendrocytes by double staining
is difﬁcult, since many cellular proteins, used as speciﬁc cell mark-
ers, are degraded in the course of apoptosis or necrosis.
Nevertheless, the selective demyelination and oligodendrocyte
apoptosis related to the expression of apoptosis-inducing factor
(Veto et al., 2010) in active multiple sclerosis lesions is in line
with the profound DNA oxidation seen in this study. The promin-
ent labelling of myelin and oligodendrocyte-like cells by immuno-
cytochemistry for MDA and oxidized phospholipids, as shown in
this study, further supports the view that oxidative damage plays a
major role in demyelination and oligodendrocyte destruction in
1922 | Brain 2011: 134; 1914–1924 L. Haider et al.active multiple sclerosis lesions. It must, however, be emphasized
that DNA oxidation in active multiple sclerosis lesions is not re-
stricted to oligodendrocytes, but also affects astrocytes in low
incidence.
Immunocytochemistry for oxidized phospholipids provided fur-
ther insights into the mechanisms of tissue injury in multiple scler-
osis lesions. Besides the presence of oxidized phospholipids in
oligodendrocytes and myelin, we also found a highly selective
and profound expression of these neo-epitopes within degenerat-
ing axons and neurons. Accumulation of oxidized phospholipids in
dystrophic axons may accumulate at sites of disturbed axonal
transport. Alternatively, they may indicate radical-mediated
damage as an initial change in axonal demise. We think that the
second possibility is more likely. The half-life of oxidized lipids in a
cell is estimated by minutes or few hours only (Keller and Matson,
1998). Furthermore, only a small fraction of amyloid precursor
protein reactive dystrophic axons were also stained for oxidized
phospholipids and they were concentrated at sites of initial lesions.
In contrast, abundant amyloid precursor protein reactive axonal
spheroids, which are present in the centre of the lesions, were
devoid of immunoreactivity for oxidized phospholipids. This sug-
gests that for the ﬁrst time it is possible to directly visualize acute
injury of axons, neuronal cell bodies or the fragmentation of their
dendrites as a direct consequence of radical-mediated injury.
Oxidized phospholipids were also present in astrocytes in active
multiple sclerosis lesions. In contrast to oligodendrocytes and neu-
rons, these cells, however, do not degenerate but appear to be
capable of sequestering damaged cytoplasmic components into
(autophagic) vacuoles. However, it has been shown before that
astrocytes, too, show signs of injury, mainly reﬂected by retraction
of their cell processes and altered expression of molecules, related
to the formation of the glia limitans (Parrat and Prineas, 2010;
Sharma et al., 2010).
It was interesting to note that different cell types within the
multiple sclerosis lesions differentially accumulated MDA and oxi-
dized phospholipids. While both types of oxidized lipid epitopes
were seen in myelin and oligodendrocytes, axons and neurons
exclusively accumulated oxidized phospholipids. One possible ex-
planation could be that the cellular content of phosphatidylcholine,
rich in polyunsaturated fatty acids, is higher in the grey matter
compared with the white matter (Svennerholm, 1968), suggesting
that such fatty acids are preferentially present in neurons and
axons.
In summary, our study provides evidence for an important role
of oxidative damage in the pathogenesis of demyelination and
neurodegeneration in multiple sclerosis lesions, which may act in
addition to, or in cooperation with nitric oxide radicals, as
described previously (Bagasra et al., 1995; Zeis et al., 2009). It
further shows—for the ﬁrst time—that the analysis of oxidized
lipid epitopes in multiple sclerosis lesions allows identiﬁcation of
acute damage of oligodendrocytes, axons and neurons at different
stages of lesion formation. Our data also suggest that oxidative
damage is in part related to inﬂammation, that it affects different
cellular components of the CNS, but that myelin, oligodendro-
cytes, neurons and axons may be more sensitive to oxidative
damage than astrocytes.
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